The significant dilution from warrant exercises combined with declining revenue and ongoing litigation creates substantial downside risk. The company's ability to continue as a going concern is in question, and traders should monitor the outcome of the Pooph litigation and the company's ability to secure additional financing.
Executive Summary
This 424B4 filing relates to the offering of 31,730,651 shares of BioLargo common stock by selling stockholders upon exercise of warrants. The company will not receive proceeds from the stock sales but could receive up to $8.4 million if all warrants are exercised. The offering follows a significant revenue decline and ongoing litigation with a former major customer, Pooph Inc., which has raised substantial doubt about the company's ability to continue as a going concern.
Key Financial Metrics
Key Facts
- 31,730,651 shares offered by selling stockholders upon exercise of warrants with average exercise price of $0.265
- Company could receive up to $8,416,462 if all warrants are exercised
- Company's revenue decreased 56% year-over-year to $7.765 million for 2025
- Company reported net loss of $15.189 million for 2025, up from $4.347 million in 2024
- Auditors' report includes going concern doubt due to recurring losses and negative cash flow
- Company is engaged in litigation with former largest customer Pooph Inc. over unpaid royalties and product payments totaling $3.8 million
Financial Impact
Dilution of approximately 9% of outstanding shares if all warrants are exercised
Risk Factors
- Substantial doubt about going concern status due to recurring losses
- Ongoing litigation with former major customer could result in material losses
- Significant dilution from warrant exercises
- Continuing revenue decline and negative cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001437749-26-012700 |
| Document: 0001437749-26-012700-index-headers.html | 0001437749-26-012700 |
| Document: 0001437749-26-012700-index.html | 0001437749-26-012700 |
| Document: 0001437749-26-012700.txt | 0001437749-26-012700 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.0700 | awaiting T+60 | — | $0.0680 (+2.86%) |
Sep 11, 2026 6w ago | 8-K | $0.1000 | awaiting T+60 | — | $0.0680 (−32.00%) |
May 4, 2026 25w ago | 8-K | $0.1600 $0.1117 | ▼ −30.19% | ▼ −32.04% | $0.0680 (−57.50%) |
Apr 17, 2026 27w ago | 424B4 | $0.1500 $0.1120 | ▲ +25.33% | ▲ +32.11% | $0.0680 (+54.67%) |
Apr 17, 2026 27w ago | 424B4 | $0.1500 $0.1120 | ▲ +25.33% | ▲ +32.11% | $0.0680 (+54.67%) |
Mar 5, 2026 33w ago | 8-K | $0.1700 $0.1200 | ▲ +29.41% | ▲ +40.71% | $0.0680 (+60.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers